Skystar Bio Pharmaceutical Company reported unaudited earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported revenues of roughly $5.5 million as compared to revenues of $7.9 million for the three months ended March 31, 2012, a decrease of $2.4 million or 30.2%. Net income was $0.7 million or $0.09 per fully diluted share, as compared with $1.9 million or $0.26 per fully diluted share a year ago.

The company reiterated fiscal 2013 revenue guidance range of $40 million to $45 million.